This article was originally published in The Gray Sheet
Firm submits PMA supplement for use of its LaserScan LSX excimer laser in LASIK surgery to correct hyeropia of +0.5D to +8.0D and hyperopic astigmatism of up to +6.0D. LaserSight submitted a PMA supplement for LASIK treatment of myopia in December 2000. Approval of a March 2000 PMA supplement submission for treatment of astigmatism using photorefractive keratectomy has been delayed by questions raised by FDA (1"The Gray Sheet" Feb. 19, 2001, In Brief)
You may also be interested in...
Firm preparing response to Feb. 7 questions by FDA on March 2000 PMA supplement for the LaserScan LSX for treatment of astigmatism using photorefractive keratectomy. In December, the firm filed a separate PMA supplement for LASIK treatment of myopia and myopic astigmatism
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.